{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:15:49Z","timestamp":1788794149581,"version":"build-2803163510"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP21K06710"],"award-info":[{"award-number":["JP21K06710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["JP21K06710"],"award-info":[{"award-number":["JP21K06710"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>This is the first study to use a large database of patients with cancer to examine the association between the studied drugs and AKI.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The use of either proton pump inhibitors or immune checkpoint inhibitors was associated with an increased risk of AKI.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>However, their additive interaction was not identified.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An association between proton pump inhibitor (PPI) use and an increased risk of AKI has been confirmed. This study aimed to evaluate the effects of PPI use on the risk of AKI in patients with cancer who were administered immune checkpoint inhibitors (ICIs), a class of drugs used in cancer treatment, and in those who were not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a database provided by the Health, Clinic, and Education Information Evaluation Institute, which included demographic data, diagnoses, prescriptions, and laboratory results. We conducted a nested case\u2013control study of 38,930 patients with cancer who were new PPI or ICI users and had no history of AKI before cohort entry. The odds ratio (OR) for AKI was estimated using conditional logistic regression models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During a mean follow-up of 8.3 months, 5870 cases of AKI were identified (incidence rate, 21.9\/100 person-years). Compared with never or past PPI use without ICI use, the adjusted ORs of AKI for current PPI use without ICI use, past or never PPI use with prior ICI use, current PPI use with prior ICI use were 2.20 (95% confidence interval [CI], 2.01 to 2.40), 1.72 (95% CI, 1.37 to 2.17), or 2.62 (95% CI, 1.75 to 3.93), respectively. The risk of AKI in patients treated with both PPIs and ICIs was not higher than the additional or multiplication of the risks in those who were treated with PPIs or ICIs alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reinforces the association between PPI and ICI use and the increased risk of AKI. Although the interaction between the two drug classes was not detected, these findings highlight the need for careful monitoring and evaluation of kidney function in patients treated with PPIs and ICIs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0000000000000528","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T17:02:49Z","timestamp":1722531769000},"page":"1262-1269","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Association between Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Acute Kidney Injury: A Nested Case\u2013Control Study"],"prefix":"10.34067","volume":"5","author":[{"given":"Chinami","family":"Yamawaki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-122X","authenticated-orcid":false,"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7640-8318","authenticated-orcid":false,"given":"Keiko","family":"Ikuta","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3003-3238","authenticated-orcid":false,"given":"Yurie","family":"Katsube","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Imayoshi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7033-5357","authenticated-orcid":false,"given":"Yuki","family":"Shigetsura","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-2469","authenticated-orcid":false,"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-9008","authenticated-orcid":false,"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"},{"name":"Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-9753","authenticated-orcid":false,"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"issue":"4","key":"B1-20250823","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology."},{"key":"B2-20250823","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/1471-2369-14-150","article-title":"Proton pump inhibitors and acute kidney injury: a nested case-control study","volume":"14","author":"Klepser","year":"2013","journal-title":"BMC Nephrol."},{"issue":"2","key":"B3-20250823","doi-asserted-by":"crossref","first-page":"E166","DOI":"10.9778\/cmajo.20140074","article-title":"Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study","volume":"3","author":"Antoniou","year":"2015","journal-title":"CMAJ Open."},{"issue":"2","key":"B4-20250823","doi-asserted-by":"crossref","first-page":"e041543","DOI":"10.1136\/bmjopen-2020-041543","article-title":"Association of proton pump inhibitors and concomitant drugs with risk of acute kidney injury: a nested case-control study","volume":"11","author":"Ikuta","year":"2021","journal-title":"BMJ Open."},{"issue":"2","key":"B5-20250823","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/ndt\/gfw470","article-title":"The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis","volume":"33","author":"Nochaiwong","year":"2018","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"B6-20250823","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"B7-20250823","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.ekir.2020.07.011","article-title":"Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors","volume":"5","author":"Seethapathy","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"2","key":"B8-20250823","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B9-20250823","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep."},{"issue":"5","key":"B10-20250823","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10157-020-02008-1","article-title":"Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study","volume":"25","author":"Shimamura","year":"2021","journal-title":"Clin Exp Nephrol."},{"issue":"5","key":"B11-20250823","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.21873\/invivo.12570","article-title":"Concomitant proton pump inhibitors and immune checkpoint inhibitors increase nephritis frequency","volume":"35","author":"Kato","year":"2021","journal-title":"In Vivo."},{"issue":"1","key":"B12-20250823","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"issue":"8","key":"B13-20250823","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep."},{"issue":"11","key":"B14-20250823","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/ckj\/sfad109","article-title":"Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis","volume":"16","author":"Miao","year":"2023","journal-title":"Clin Kidney J."},{"issue":"10","key":"B15-20250823","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer."},{"issue":"6","key":"B16-20250823","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00403-024-03061-6","article-title":"Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases","volume":"316","author":"Bray","year":"2024","journal-title":"Arch Dermatol Res."},{"issue":"9","key":"B17-20250823","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1592\/phco.24.13.1105.38083","article-title":"Pharmacoepidemiology II: the nested case-control study--a novel approach in pharmacoepidemiologic research","volume":"24","author":"Etminan","year":"2004","journal-title":"Pharmacotherapy."},{"issue":"10","key":"B18-20250823","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2183\/pjab.98.026","article-title":"Clinical epidemiology and pharmacoepidemiology studies with real-world databases","volume":"98","author":"Yoshida","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci."},{"issue":"7","key":"B19-20250823","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1111\/bcp.15252","article-title":"Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity","volume":"88","author":"Imai","year":"2022","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"B20-20250823","doi-asserted-by":"crossref","first-page":"e002636","DOI":"10.1136\/bmjdrc-2021-002636","article-title":"Initiating SGLT2 inhibitor therapy to improve renal outcomes for persons with diabetes eligible for an intensified glucose-lowering regimen: hypothetical intervention using parametric g-formula modeling","volume":"10","author":"Takeuchi","year":"2022","journal-title":"BMJ Open Diabetes Res Care."},{"issue":"9","key":"B21-20250823","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.34067\/KID.0000000000000204","article-title":"Anemia treatment, hemoglobin variability, and clinical events in patients with nondialysis-dependent CKD in Japan","volume":"4","author":"Kuragano","year":"2023","journal-title":"Kidney360."},{"key":"B22-20250823","doi-asserted-by":"crossref","first-page":"106129","DOI":"10.1016\/j.cmpb.2021.106129","article-title":"Prediction and visualization of acute kidney injury in intensive care unit using one-dimensional convolutional neural networks based on routinely collected data","volume":"206","author":"Sato","year":"2021","journal-title":"Comput Methods Programs Biomed."},{"issue":"1","key":"B23-20250823","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12882-022-03008-x","article-title":"Use of proton pump inhibitors and macrolide antibiotics and risk of acute kidney injury: a self-controlled case series study","volume":"23","author":"Ikuta","year":"2022","journal-title":"BMC Nephrol."},{"issue":"12","key":"B24-20250823","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1093\/ndt\/gfs375","article-title":"A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy","volume":"27","author":"Fliser","year":"2012","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B25-20250823","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000439146","article-title":"Standardizing the early identification of acute kidney injury: the NHS england national patient safety alert","volume":"131","author":"Selby","year":"2015","journal-title":"Nephron."},{"issue":"2","key":"B26-20250823","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1053\/j.ajkd.2019.05.031","article-title":"Timing of recovery from moderate to severe AKI and the risk for future loss of kidney function","volume":"75","author":"Siew","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"4","key":"B27-20250823","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nrneph.2017.2","article-title":"Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup","volume":"13","author":"Chawla","year":"2017","journal-title":"Nat Rev Nephrol."},{"issue":"4","key":"B28-20250823","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol."},{"issue":"1","key":"B29-20250823","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"1","key":"B30-20250823","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/ndt\/gfy105","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","journal-title":"Nephrol Dial Transplant."},{"issue":"12","key":"B31-20250823","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol."},{"issue":"11","key":"B32-20250823","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care."},{"issue":"6","key":"B33-20250823","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10654-011-9554-9","article-title":"Estimating measures of interaction on an additive scale for preventive exposures","volume":"26","author":"Knol","year":"2011","journal-title":"Eur J Epidemiol."},{"issue":"2","key":"B34-20250823","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/ije\/dyr218","article-title":"Recommendations for presenting analyses of effect modification and interaction","volume":"41","author":"Knol","year":"2012","journal-title":"Int J Epidemiol."},{"issue":"4","key":"B35-20250823","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ki.2014.74","article-title":"A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use","volume":"86","author":"Blank","year":"2014","journal-title":"Kidney Int."},{"issue":"7","key":"B36-20250823","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v9.i7.63","article-title":"Potassium-competitive acid blockers - are they the next generation of proton pump inhibitors?","volume":"9","author":"Rawla","year":"2018","journal-title":"World J Gastrointest Pharmacol Ther."},{"issue":"5","key":"B37-20250823","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut."},{"issue":"4","key":"B38-20250823","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/19490976.2017.1284732","article-title":"The influence of proton pump inhibitors and other commonly used medication on the gut microbiota","volume":"8","author":"Imhann","year":"2017","journal-title":"Gut Microbes."},{"issue":"5","key":"B39-20250823","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut."},{"issue":"1","key":"B40-20250823","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology."}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000528","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:00:32Z","timestamp":1786478432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000000000000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000000000000528","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"2024-04-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}